Business Context and Reporting Period
VistaGen Therapeutics, Inc. (VTGN) filed this Form 8-K on August 19, 2019, regarding a notice received from The Nasdaq Stock Market, LLC. The company is incorporated in Nevada and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. The primary financial metric disclosed is the company's stockholders' equity, which was reported as below the $2.5 million minimum requirement set forth in Nasdaq Listing Rule 5550(b)(1) as of June 30, 2019, based on the Company's Form 10-Q for that quarter.
Material Changes and Listing Status
- Equity Deficiency: Nasdaq notified the company of non-compliance with the minimum stockholders' equity requirement as of June 30, 2019.
- Compliance Timeline: The company has 45 calendar days (until October 3, 2019) to regain compliance or submit a plan to do so.
- Extension Possibility: If a plan is accepted, Nasdaq may grant an additional 180-day extension (until February 15, 2020) to provide evidence of compliance.
- Current Listing Status: The notice has no immediate effect on the listing of the company's common stock.
- Prior Notice: This follows a previous notice received on June 17, 2019, regarding the same equity requirement.
Outlook, Risks, and Management Commentary
Management intends to promptly evaluate various courses of action to submit a plan and regain compliance. However, the filing explicitly states there is no assurance that the company will regain compliance within the 45-day period, secure an extension, or maintain compliance with other listing requirements.
Additional Risk: The company remains subject to potential delisting based on the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). If the stock fails to meet this requirement for at least ten consecutive business days prior to December 16, 2019, delisting will proceed regardless of the equity compliance outcome.
Investor Verification Checklist
- Verify the exact stockholders' equity figure reported in the Form 10-Q for the quarter ended June 30, 2019.
- Monitor the company's stock price to assess risk of delisting under the minimum bid price rule by December 16, 2019.
- Watch for the submission of a compliance plan to Nasdaq by October 3, 2019.
- Review any subsequent filings regarding capital raising efforts or equity restructuring intended to meet the $2.5 million threshold.